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SUMMARY
We consider the construction of efficient group sequential designs where the goal is a low expected
sample size not only at the null hypothesis and the alternative (taken to be the minimal clinically
meaningful effect size), but also at more optimistic anticipated effect sizes. Pre-specified Type I error
rate and power requirements can be achieved both by standard group sequential tests and by more
recently proposed adaptive procedures. We investigate four nested classes of designs: (A) Group
sequential tests with equal group sizes and stopping boundaries determined by a monomial error
spending function (the “ρ-family”); (B) As A but the initial group size is allowed to be different
from the others; (C) Group sequential tests with arbitrary group sizes and arbitrary boundaries, fixed
in advance; (D) Adaptive tests — as C but at each analysis, future group sizes and critical values
are updated depending on the current value of the test statistic. By examining the performance of
optimal procedures within each class, we conclude that class B provides simple and efficient designs
with efficiency close to that of the more complex designs of classes C and D. We provide tables and
figures illustrating the performances of optimal designs within each class and defining the optimal
procedures of classes A and B. Copyright c© 2000 John Wiley & Sons, Ltd.
KEY WORDS: clinical trial; group sequential test; sample size re-estimation; adaptive design;
flexible design; optimal design; error spending function
1. INTRODUCTION
Along with practical considerations, the sample size for a clinical trial is determined by setting
up null and alternate hypotheses concerning a primary parameter of interest, θ, and then
specifying a Type I error rate α and power 1−β to be controlled at a given treatment effect size
θ = ∆. Usually, traditional values of α and β are used (e.g., α = 0.025, 0.05, β = 0.05, 0.1, 0.2);
however, there can be much debate over the choice of ∆. Some textbooks advocate that ∆
should be chosen to represent the minimum “clinically relevant” or “commercially viable” effect
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size — see for example Senn [1, p. 170] and Piantadosi [2, p. 149]. Others such as Shun et al.[3]
say that ∆ can be taken to be the anticipated effect size — a value based on expectations
from prior experimental, observational and theoretical evidence. Pocock[4] suggests that either
approach might be taken: on pages 125 and 132, ∆ is to be a “realistic value”, while in the
example on page 128, it is to be a “clinically relevant” difference that is “important to detect”.
In Section 3.5 of the ICH Guidance E9 [5], it is also stated that ∆ is to be based on a judgement
concerning either the minimal clinically relevant effect size or the “anticipated” effect.
The choice of ∆ is crucial because, for example, a halving in the chosen effect size will lead
to a quadrupling in the sample size for a fixed sample test (and in the maximum sample size
for a group sequential test). Using the lower sample size appropriate to a high treatment effect
will leave the trial underpowered to detect a smaller but still important effect. Because of
this, Shun et al.[3] and others have proposed that the trial be designed using the higher effect
size (and corresponding lower sample size), but that sample size be re-estimated at an interim
analysis based on the emerging observed treatment difference. This has been termed the “start
small then ask for more” strategy[6]. Liu and Chi[7] present formal two-stage designs in which
the first stage sample size is sufficient to provide specified power at an expected effect size but
additional observations in the second stage increase power at smaller effect sizes and guarantee
an overall power requirement at a minimal clinically significant treatment effect.
There have been several accounts in the literature of studies in which sample size has
been adapted in order to increase power at lower effect sizes. Cui et al.[8] report on a
placebo controlled myocardial infarction prevention trial with a sample size of 600 subjects
per treatment arm, this number being based on a planned effect size of a 50% reduction in
incidence and 95% power. However midway through the trial, only about a 25% reduction
in incidence was observed, a reduction which was still of clinical and commercial importance.
Because of the low conditional power at this stage, the sponsor of the trial submitted a proposal
to expand the sample size. In recent years, classes of procedures termed “flexible”, “adaptive”,
“self-designing” or “variance spending” have been developed which enable such sample size
re-estimation to be done while preserving the Type I error rate α. See Bauer[9]), Proschan
and Hunsberger[10], Fisher[11]), Cui et al.[8], Wassmer[12], Li et al.[13], and Posch et al.[14]
among others.
Remarks by some authors, e.g., Shen and Fisher[15] and Shun et al.[3], suggest a desire to
set a specific power, 1 − β, at whatever is the true value of the effect size parameter. This
aim may lead to adaptive designs with a power curve rising sharply from α at θ = 0, then
remaining almost flat at 1− β. In consequence, significant risk of a negative outcome remains
even when the effect size is high and power close to one could easily have been attained.
All the above discussion supports the view that a clinical trial should guarantee power
at effect sizes θ of clinical or commercial interest. Smaller effects are not pertinent since, as
Shih [16, p. 517] states “. . . trials need to consider sample size to detect a difference that is
clinically meaningful, not merely to find a statistical significance.” Limitations occur when the
sample size needed to detect a particularly small effect is prohibitive: then, power must be
specified at the smallest value of θ that resources permit.
Shun et al. [3, p. 520] give an example of the dilemma investigators can face: It is agreed
that the minimum clinically meaningful effect is θ = 5 but the anticipated effect size if θ = 10.
Should the trial be planned with the large sample size necessary to deliver power under θ = 5?
Or, should one start with the lower sample size required for power under θ = 10 then carry
out a review when interim data are available to estimate θ, increasing the sample size if this
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interim estimate is lower than 10? Shun et al.[3] favour the second, adaptive approach “in
order to possibly save resources”. They do not, however, consider the option of a sequential
test designed to achieve power under θ = 5 which would be likely to stop early, after only a
fraction of the planned maximum sample size, if the true value of θ were as high as 10. Our
objective in this paper is to compare the non-adaptive and adaptive approaches to the design
of such a study.
Our premise is that traditional non-adaptive group sequential tests and more recent adaptive
designs are fundamentally similar in form. Their implementation can be summarised as:
Sample the first stage with its specified group size,
decide whether to stop or continue,
(if adaptive) choose group sizes and stopping boundary values
for second stage in the light of first stage data
sample the second stage with its specified group size,
decide whether to stop or continue,
(if adaptive) choose group sizes and stopping boundary values
for third stage in the light of second stage data,
etc.
A common goal underlies both types of test and this goal can be phrased in terms of the
overall power curve, i.e., the power investigators wish their study to achieve as a function
of the true value of θ. For example, in the situation described by in [3] it is clear that high
power is required if θ is actually equal to 5, so the overall power curve of an acceptable design
must take a suitably high value at θ = 5. Note that this requirement holds independently
of any additional evidence that θ is equal to 5: the point is that if θ = 5, then the overall
design package should provide a high probability of declaring a positive finding. The efficiency
with which a test, adaptive or non-adaptive, attains its desired power can be measured by the
expected sample size it consumes in doing this which, again, should be studied as a function
of the true effect size.
Many proposals for adaptive study designs base mid-course revisions of the remaining sample
size on the conditional power under particular θ values. It is important not to confuse this
conditional power with the overall power curve of the study design. Once the prescription
for an adaptive trial design is set out as, for example, in the procedures defined by Proschan
and Hunsberger[10] or Li et al.[13], the plan the trial will follow as it progresses is completely
defined and one can compute the procedure’s overall power curve. Initially, when a suitable
design is being chosen for a forthcoming study, it is the overall power that investigators need
to consider.
An attraction of certain adaptive schemes is that they allow freedom to make changes in
response to interim data that were not considered before the study started. Even then one
can, at least conceptually, define a specific procedure by asking what changes would have been
made under all possible sequences of observations. Then, the performance of this realisation
of a “flexible monitoring scheme” is that of the pre-specified adaptive design defined by these
rules. Thus, in evaluating the class of pre-specified adaptive designs, we shall also learn what
flexible designs, which are not fully pre-specified, can offer.
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The flexibility of adaptive designs can also be used to react to external information that
affects a study’s objectives. While this is an important property, it is quite distinct from the
issue we shall address in our comparisons of sequential designs. In what follows, we confine our
attention to the relatively simple situation where the external environment remains constant
during the course of a study. We comment further on adaptation to external factors in Section 5.
In comparing designs, we shall study tests with a specific Type I error rate, α, and power
1 − β at a given effect size θ = ∆, noting it is the overall power of the complete procedure
that we consider here, however this is achieved. We shall compare designs with respect to their
expected sample size (or average sample number, “ASN”) over the range of θ values of interest.
In our formulation, ∆ represents the minimum clinically or commercially meaningful effect,
and thus ASN should also be considered at the larger effect size that investigators are hoping
for, θ = L∆, say, where L > 1. Combining ASN at these two points with the ASN under the
null hypothesis θ = 0 gives our optimality criterion
1
3
{ASN(θ = 0) +ASN(θ = ∆) +ASN(θ = L∆)}. (1)
This criterion reflects equipoise and a balance between optimism and pessimism. We have also
made investigations using other criteria, generalised to include additional θ values or varying
the assigned weights, and obtained qualitatively similar conclusions.
We shall assess three classes, A, B and C, of conventional group sequential tests, moving
from simple to more complex designs. There are a great many proposals from which to choose
types of adaptive design and in our studies of these methods we have often found adaptive
designs to have inferior performance to well chosen non-adaptive group sequential tests; see
Jennison and Turnbull[17] for one such case study. However, the class of adaptive tests contains
non-adaptive tests as special cases so it is clear that efficient adaptive designs must exist! As
our fourth class, D, we consider all possible adaptive designs, i.e., group sequential tests in
which, at any stage, future group sizes and decision boundaries can be adapted to observed
responses in a pre-planned way. The idea of seeking optimal tests within this class was proposed
by Schmitz[18] who referred to these as “sequentially planned sequential designs”. Since this
class contains all possible adaptive designs, the optimal designs we find for a given criterion
will perform at least as well, by this criterion, as any adaptive or flexible test that one might
propose.
The recent paper of Scha¨fer and Mu¨ller [19] has also addressed the issue of uncertainty about
the effect size to be detected, taking a somewhat different approach. For a K-group trial with
Type I error rate α, these authors consider a sequence of K values of θ, L1∆ < . . . < LK∆,
and show how to construct boundaries such that, for each k = 1, . . . ,K, the probability of
stopping to reject H0 at or before the kth analysis is equal to 1−β when θ = Lk∆. In contrast,
our emphasis is on the ASN under different θ values, subject to the goal of protecting power
at the most pessimistic effect size θ = ∆. Scha¨fer and Mu¨ller’s [19] procedures belong to our
class C and, hence, results for the optimal test in class C provide an upper bound on how well
these designs perform by our criteria.
2. GROUP SEQUENTIAL PROCEDURES
Consider a balanced two-sample comparison in which observations XAi on treatment A and
XBi on treatment B, i = 1, 2, . . . , are independent, normally distributed with common, known
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variance σ2 and unknown means µA and µB , respectively. The parameter of interest is the
difference in treatment means, θ = µA − µB , and it is desired to test the null hypothesis H0:
θ = 0 against the one-sided alternative θ > 0 with Type I error probability α. Although this
problem may seem unrealistically simple, it does in fact serve as a prototype for a wide variety
of designs and response types: methods developed for this situation have wide applicability —
see, for example, Jennison and Turnbull [20, Chap. 3].
The assumption of known variance is significant here as it means we are not concerned with
adapting sample size in response to new estimates of σ2. There is a considerable literature on
adaptive methods for “re-estimating” the sample size needed to meet a fixed power requirement
as more is learnt about a nuisance parameter; see, for example, Wittes and Brittain[21]
and Gould and Shih[22] or, for updating sample size in a group sequential test, Denne and
Jennison[23] and Mehta and Tsiatis[24]. However, we do not consider this question in the
present paper. We refer readers to Schwartz and Denne[25] for a careful explanation of how
multi-stage designs can incorporate one or more of the objectives of: updating sample size in
response to new variance estimates; adjusting sample size as the effect size to be detected is
modified; stopping early according to a group sequential rule as soon as the observed data
permit this.
For our stated problem, a fixed sample test attaining power 1− β at the alternative θ = ∆
requires a sample size
nf =
2σ2(zα + zβ)2
∆2
(2)
per treatment arm where zp = Φ−1(1 − p) denotes the upper p tail point of the standard
normal distribution. The test statistic is given by
Z =
1√
(2σ2nf )
nf∑
i=1
(XAi −XBi) (3)
and H0 is rejected if and only if Z > zα.
In a group sequential design, the accumulating data are analysed repeatedly. Suppose the
maximum number of analyses is set at K and, for k = 1, . . . ,K, the cumulative number of
observations per treatment arm at analysis k is nk, where of course n1 < . . . < nK . At analysis
k, the statistic
Zk =
nk∑
i=1
(XAi −XBi)/(σ
√
2nk)
is computed. A general one-sided group sequential test is defined by pairs of constants (ak, bk)
with ak < bk for k = 1, . . . ,K − 1 and aK = bK . It takes the form:
After group k = 1, . . . ,K − 1
if Zk ≥ bk stop, reject H0
if Zk ≤ ak stop, accept H0
otherwise continue to group k + 1,
after group K
if ZK ≥ bK stop, reject H0
if ZK < aK stop, accept H0.
(4)
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Here, aK = bK ensures that the test terminates at analysis K.
In order for the group sequential test to achieve Type I error probability α and power 1− β
at θ = ∆, its maximum sample size, nK , must be at least a little larger than the fixed sample
size nf . The ratio R = nK/nf is termed the inflation factor of a group sequential test.
There are many choices of boundary {(ak, bk); k = 1, . . . ,K}, that will satisfy the α and
β error probability requirements. One convenient definition is through the specification of a
parametric error spending function. Following Jennison and Turnbull [20, Chap. 7.3.2], we
define two error spending functions f(t) and g(t), for Type I and Type II errors respectively,
which are non-decreasing and satisfy f(0) = g(0) = 0, f(1) = α and g(1) = β. The critical
values (ak, bk), k = 1, . . . ,K, are calculated by solving successively
Prθ=0{a1<Z1<b1, . . . , ak−1<Zk−1<bk−1, Zk≥bk} = f(nk/nK)− f(nk−1/nK) (5)
and
Prθ=δ{a1<Z1<b1, . . . , ak−1<Zk−1<bk−1, Zk≤ak} = g(nk/nK)− g(nk−1/nK), (6)
starting with a1 and b1 at the first analysis, where we take n0 = 0, and proceeding up to
k = K. For given functions f(t) and g(t), the requirement aK = bK at the final analysis
determines the necessary maximum sample size nK and, hence, the test’s inflation factor
R = nK/nf . Various software programs are available to aid this computation; for example,
the commercial packages East3 [26] and S+SeqTrial 2.0 [27], or those freely available at the
website http://www.medsch.wisc.edu/landemets/.
We shall consider the simple error spending functions:
f(t) = αtρ and g(t) = βtρ, (7)
parametrized by the single parameter ρ > 0. This choice defines the so-called “ρ-family”
of tests. There is a one-to-one relationship between the value of ρ and the inflation factor
R = nK/nf ; this relationship is illustrated in Table 7.6 of [20] for the case of equally sized
groups and selected values of K, α and β.
A referee has commented on our assumption that the study will definitely stop with
acceptance of H0 if ever Zk ≤ ak and noted that if sampling were to continue in such
circumstances, this would inflate the Type I error rate above α. If there is concern that the
Data and Safety Monitoring Board may not adhere rigidly to the stopping boundaries specified
in the study protocol, the Type I error rate can be protected by replacing (5) with
Prθ=0{Z1<b1, . . . , Zk−1<bk−1, Zk≥bk} = f(nk/nK)− f(nk−1/nK).
Then, if the stopping rule is followed precisely, the Type I error rate will be achieved
conservatively. Since this conservatism would complicate our comparison of different types
of test, we shall continue with our original definition for the remainder of this paper.
We shall study four families of group sequential tests (GSTs) comprising two forms of error
spending test, general non-adaptive GSTs, and adaptive GSTs. To ensure a fair comparison,
tests in all families must meet the same design specifications given by α, β, ∆ and K. It is well
known that group sequential tests can yield greater reductions in ASN as the inflation factor
R increases; see, for example, Eales and Jennison[28]. Practical constraints will often limit
the maximum possible sample size and, hence, the values allowable for R. We have derived
optimal tests for fixed values of R but we also report results without this constraint, obtained
by optimising freely over R.
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A. Equal group sizes. These tests are ρ-family error spending tests with equally spaced
analyses: nk = (k/K)Rnf , k = 1, . . . ,K. Since the value of ρ is determined by R, there
is only one test for a given design specification. Planning with equal group sizes is the
usual starting point when designing a GST.
B. Proposed class of GSTs. These are ρ-family error spending tests with one degree of
freedom in setting group sizes. The first group size is n1 and remaining analyses are
equally spaced thereafter: nk = n1 + (Rnf − n1)(k − 1)/(K − 1), k = 2, . . . ,K. If the
treatment difference is as high as L∆, where L > 1, there may be opportunity for early
stopping well before the first analysis in procedure A: scheduling an early look helps
lower the ASN in this case, reducing the overall criterion (1). Optimization is over the
choice of n1, after which ρ is determined by R.
C. Optimal non-adaptive GSTs. Complete freedom is allowed in choosing critical values
(ak, bk) and cumulative sample sizes n1, . . . , nK to optimize the criterion (1), subject to
nK ≤ Rnf . Note that the choice of nk and (ak, bk), k = 1, . . . ,K, is set at the start of
the study and cannot be updated as observations accrue.
D. Optimal adaptive GSTs. These are fully adaptive designs. At each analysis k =
1, . . . ,K − 1, the next cumulative group size nk+1 and critical values (ak+1, bk+1) are
chosen based on current data. The whole procedure is chosen to optimize criterion (1)
subject to nK ≤ Rnf .
Optimal non-adaptive tests for a fixed sequence of group sizes are derived using methods
described in [28] for the symmetric case, α = β, and in Barber and Jennison[29] for the
asymmetric case. A Bayes decision theory problem is set up and the solution found by a
backward induction (dynamic programming) technique. A search over decision and sampling
costs leads to a Bayes problem with solution equal to the optimal GST being sought. Further
optimization over group sizes n1, . . . , nK as described in [28, Sec. 5] provides the optimal tests
within class C. Construction of the optimal adaptive or “Schmitz” [18] tests in class D proceeds
by use of the dynamic programming technique in a generalization of the Bayes decision problem
where group size is allowed to depend on the current value of the statistic Zk.
3. OPTIMAL TESTS AND THEIR PROPERTIES
We present results for tests with Type I error rate α = 0.025, power 1− β = 0.8 at θ = ∆ and
a maximum of K analyses where K = 2, 3, 4, 5 or 6. Tests are optimized for the average ASN
criterion (1) with L = 2 and 4. All calculations are by numerical integration and results are
accurate to at least the number of decimal places shown in the tables.
Figures 1 and 2 show how the optimized average ASN varies with R for tests with 2 and
5 analyses, respectively. For both classes A and B of ρ-family tests, average ASN decreases
initially as R increases but eventually starts to increase again. The group sizes of class C tests
are optimized subject to the constraint nK/nf ≤ R: initially the optimal tests have nK/nf = R
but as R is increased a value, R˜C say, is reached such that the optimal test continues to take
nK/nf = R˜C even though higher values are allowed. Similarly, for given L and K, there is a
maximal inflation factor, R˜D say, for optimal tests in class D: even when larger values of nK
are permitted, all sample paths terminate with nK ≤ R˜Dnf . The points at which the curves
for classes C and D reach their plateaus are marked in the figures but it is clear that values
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Figure 1. Optimized average ASN plotted against R for tests in classes A to D. Tests have Type I
error rate α = 0.025, power 1 − β = 0.8 at θ = ∆, a maximum of K = 2 analyses, and minimize
the average ASN criterion {ASN(θ = 0) + ASN(θ = ∆) + ASN(θ = L∆)}/3 for L = 2 and 4. The
symbols 2 on the curves for classes C and D indicate the values of R at which these curves become
flat.
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Figure 2. Optimized average ASN plotted against R for tests in classes A to D. Tests have Type I
error rate α = 0.025, power 1 − β = 0.8 at θ = ∆, a maximum of K = 5 analyses, and minimize
the average ASN criterion {ASN(θ = 0) + ASN(θ = ∆) + ASN(θ = L∆)}/3 for L = 2 and 4. The
symbols 2 on the curves for classes C and D indicate the values of R at which these curves become
flat.
close to the optimal average ASN are reached well before these points. Given the practical
disadvantages of a high value of R, it is reasonable to choose an inflation factor considerably
lower than these otherwise “optimal” values.
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Table I. Properties of tests with Type I error rate α = 0.025 and power 1 − β = 0.8 at θ = ∆ which
minimize criterion (1) with L = 2. The value of R is also chosen optimally to minimize this criterion.
K Design ρ R First ASN at Average
group θ=0 θ=∆ θ=2∆ ASN
1 Fixed 1.00 100.0 100.0 100.0 100.0 100.0
2 A: ρ-family, equal groups 1.36 1.09 54.5 68.1 83.3 56.4 69.3
B: ρ-family, opt. 1st group 0.67 1.21 43.0 64.5 86.3 48.9 66.6
C: Optimal non-adaptive − 1.21 43.0 63.2 86.8 49.3 66.4
D: Optimal adaptive − 1.31 41.9 63.9 85.7 48.1 65.9
3 A: ρ-family, equal groups 0.96 1.21 40.3 58.5 77.1 45.2 60.3
B: ρ-family, opt. 1st group 0.61 1.34 33.1 56.4 78.7 42.1 59.1
C: Optimal non-adaptive − 1.38 30.5 53.5 79.9 40.0 57.8
D: Optimal adaptive − 1.57 28.3 53.7 78.6 38.2 56.8
4 A: ρ-family, equal groups 0.77 1.31 32.8 53.5 74.3 39.9 55.9
B: ρ-family, opt. 1st group 0.59 1.41 27.6 52.3 75.4 38.4 55.4
C: Optimal non-adaptive − 1.53 24.4 48.9 76.2 36.0 53.7
D: Optimal adaptive − 1.80 21.6 48.8 74.8 33.9 52.5
5 A: ρ-family, equal groups 0.67 1.39 27.8 50.6 72.8 36.8 53.4
B: ρ-family, opt. 1st group 0.56 1.46 23.9 49.8 73.6 35.9 53.1
C: Optimal non-adaptive − 1.64 20.9 46.4 73.9 33.7 51.3
D: Optimal adaptive − 2.02 20.2 45.9 72.0 32.1 50.0
6 A: ρ-family, equal groups 0.60 1.45 24.2 48.6 71.9 34.7 51.7
B: ρ-family, opt. 1st group 0.55 1.49 21.8 48.2 72.4 34.3 51.6
C: Optimal non-adaptive − 1.77 18.5 44.7 72.3 32.2 49.8
D: Optimal adaptive − 2.21 17.7 44.1 70.4 30.7 48.4
Tables I and II give further details of the procedures with optimal performance over R in
Figures 1 and 2, respectively, taking R = R˜C for class C and R = R˜D for class D. In addition,
these tables give results for tests with 3, 4 and 6 analyses. In view of the practical benefits
of a low maximum sample size, we would recommend choosing values for the inflation factor
R below the global optimum. Tables III and IV give details of tests optimising criterion (1),
with L = 2 and 4 respectively, with R fixed at 1.2; however, where the minimum average ASN
occurs at a value of R below 1.2, this value is used instead. Further tables of results, similar
to Tables III and IV with R = 1.05, 1.1, 1.2, 1.3 and 1.4 and power 0.8 and 0.9 are available
at our website http://www.bath.ac.uk/∼mascj/.
The first column of each table shows the maximum number of analyses K, the fixed sample
test with K = 1 serving as a benchmark for the others. For each K ≥ 2, properties of the
optimal tests in classes A to D are presented. The value of ρ is given for the ρ-family tests
in classes A and B, then, for all four tests, we show the inflation factor R, the size of the
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Table II. Properties of tests with Type I error rate α = 0.025 and power 1− β = 0.8 at θ = ∆ which
minimize criterion (1) with L = 4. The value of R is also chosen optimally to minimize this criterion.
K Design ρ R First ASN at Average
group θ=0 θ=∆ θ=4∆ ASN
1 Fixed 1.00 100.0 100.0 100.0 100.0 100.0
2 A: ρ-family, equal groups 1.46 1.08 54.0 68.3 83.5 54.0 68.6
B: ρ-family, opt. 1st group 0.64 1.20 32.6 67.1 91.1 32.6 63.6
C: Optimal non-adaptive − 1.18 30.0 64.1 94.3 30.0 62.8
D: Optimal adaptive − 1.26 30.2 64.4 92.6 30.2 62.4
3 A: ρ-family, equal groups 1.19 1.16 38.7 59.3 77.5 38.7 58.5
B: ρ-family, opt. 1st group 0.68 1.29 17.8 60.4 82.1 18.5 53.7
C: Optimal non-adaptive − 1.35 17.6 54.3 82.6 18.8 51.9
D: Optimal adaptive − 1.50 18.0 53.6 81.3 18.7 51.2
4 A: ρ-family, equal groups 1.05 1.22 30.5 54.7 74.5 30.5 53.2
B: ρ-family, opt. 1st group 0.63 1.38 14.8 54.3 77.3 16.2 49.3
C: Optimal non-adaptive − 1.51 14.9 49.1 77.3 16.6 47.7
D: Optimal adaptive − 1.72 13.8 48.5 75.9 15.2 46.5
5 A: ρ-family, equal groups 0.95 1.27 25.4 51.8 72.7 25.4 50.0
B: ρ-family, opt. 1st group 0.61 1.43 13.3 51.0 74.8 15.2 47.0
C: Optimal non-adaptive − 1.60 12.6 46.4 74.8 14.8 45.3
D: Optimal adaptive − 1.93 11.6 45.6 72.9 13.5 44.0
6 A: ρ-family, equal groups 0.88 1.31 21.8 49.9 71.6 21.9 47.8
B: ρ-family, opt. 1st group 0.60 1.46 12.2 49.1 73.3 14.4 45.6
C: Optimal non-adaptive − 1.69 10.5 44.8 73.1 13.2 43.7
D: Optimal adaptive − 2.11 8.4 44.1 71.4 11.8 42.4
first group of observations, the ASNs under θ = 0, ∆ and L∆, and the average of these three
ASNs which forms the optimality criterion (1). All group sizes and ASNs are expressed as a
percentage of nf , the sample size required by a fixed sample test.
Our key conclusion from these figures and tables is that ρ-family error spending tests offer
simple and efficient designs for the objectives under consideration. The robust efficiency of
ρ-family tests when compared to general non-adaptive GSTs with equal group sizes has been
noted by Barber and Jennison[29]. It is evident from our results that restricting to equal group
sizes hinders the reduction of ASN at the high effect sizes of θ = 2∆ and θ = 4∆. However,
allowing choice of just the first group size in class B tests overcomes this difficulty, leading to
noticeable improvements over the class A designs for K = 2 when L = 2 and for K up to 4 or
5 when L = 4. The first group sizes in the optimal class B test are much lower for L = 4 than
for L = 2, showing how optimism about the size of treatment effect leads to a more aggressive
strategy in the hope of a “home run” finding under θ = L∆. But, despite the focus when
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Table III. Properties of tests with Type I error rate α = 0.025 and power 1− β = 0.8 at θ = ∆ which
minimize criterion (1) with L = 2. The value of R is fixed at 1.2 unless a lower value minimizes (1).
K Design ρ R First ASN at Average
group θ=0 θ=∆ θ=2∆ ASN
1 Fixed 1.00 100.0 100.0 100.0 100.0 100.0
2 A: ρ-family, equal groups 1.36 1.09 54.5 68.1 83.3 56.4 69.3
B: ρ-family, opt. 1st group 0.69 1.20 43.0 64.6 86.2 48.9 66.6
C: Optimal non-adaptive − 1.20 43.0 63.3 86.7 49.3 66.4
D: Optimal adaptive − 1.20 43.2 64.0 85.3 49.0 66.1
3 A: ρ-family, equal groups 1.00 1.20 40.0 58.6 77.2 45.1 60.3
B: ρ-family, opt. 1st group 0.99 1.20 33.8 58.1 78.0 43.0 59.7
C: Optimal non-adaptive − 1.20 31.1 55.1 79.5 40.9 58.5
D: Optimal adaptive − 1.20 28.8 54.9 78.9 39.5 57.8
4 A: ρ-family, equal groups 1.13 1.20 30.0 55.1 74.7 40.0 56.6
B: ρ-family, opt. 1st group 1.13 1.20 28.7 55.1 74.8 39.8 56.5
C: Optimal non-adaptive − 1.20 25.6 51.7 76.2 37.5 55.1
D: Optimal adaptive − 1.20 24.0 50.9 75.2 36.0 54.0
5 A: ρ-family, equal groups 1.22 1.20 24.0 53.4 73.2 37.7 54.8
B: ρ-family, opt. 1st group 1.22 1.20 25.2 53.4 73.1 37.8 54.7
C: Optimal non-adaptive − 1.20 22.6 49.8 74.3 35.7 53.2
D: Optimal adaptive − 1.20 21.6 48.8 73.0 34.2 52.0
6 A: ρ-family, equal groups 1.28 1.20 20.0 52.3 72.2 36.4 53.6
B: ρ-family, opt. 1st group 1.28 1.20 22.9 52.3 72.0 36.4 53.6
C: Optimal non-adaptive − 1.20 20.4 48.6 73.1 34.5 52.1
D: Optimal adaptive − 1.20 19.2 47.5 71.8 33.0 50.8
L = 4 on a very low ASN under θ = 4∆, ASNs at θ = 0 and ∆ are still quite similar to those
for the case L = 2. Comparisons with optimum non-adaptive tests in class C show that very
little efficiency is lost by settling on the ρ-family tests of class B: adding a free choice of all
group sizes and stopping boundary {(ak, bk); k = 1, . . . ,K} reduces average ASN by at most
2% of nf .
If we compare optimal class C and class D tests, either optimized over R or at a fixed value
of R, the improvement in passing from optimal non-adaptive tests to optimal adaptive tests
is a drop in average ASN of at most 1.4% of nf . As we explained earlier, class D contains
all varieties of adaptive test, thus our results provide an upper bound on how well specific
proposals, for example, those of Proschan and Hunsberger[10] or Shen and Fisher[15], can
perform when assessed in terms of their overall power and ASN functions. Comparing our
results for tests in classes B and D, we deduce that for the cases considered, using criterion (1)
with L = 2 or L = 4, ρ-family error spending tests with an optimized first group size have
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Table IV. Properties of tests with Type I error rate α = 0.025 and power 1− β = 0.8 at θ = ∆ which
minimize criterion (1) with L = 4. The value of R is fixed at 1.2 unless a lower value minimizes (1).
K Design ρ R First ASN at Average
group θ=0 θ=∆ θ=4∆ ASN
1 Fixed 1.00 100.0 100.0 100.0 100.0 100.0
2 A: ρ-family, equal groups 1.46 1.08 54.0 68.3 83.5 54.0 68.6
B: ρ-family, opt. 1st group 0.64 1.20 32.6 67.1 91.1 32.6 63.6
C: Optimal non-adaptive − 1.18 30.0 64.1 94.3 30.0 62.8
D: Optimal adaptive − 1.20 28.8 65.1 93.5 28.8 62.5
3 A: ρ-family, equal groups 1.19 1.16 38.7 59.3 77.5 38.7 58.5
B: ρ-family, opt. 1st group 0.92 1.20 17.6 61.9 81.4 18.6 53.9
C: Optimal non-adaptive − 1.20 18.0 55.7 82.3 19.2 52.4
D: Optimal adaptive − 1.20 16.8 55.2 82.1 18.0 51.8
4 A: ρ-family, equal groups 1.13 1.20 30.0 55.1 74.7 30.0 53.3
B: ρ-family, opt. 1st group 1.09 1.20 15.3 56.7 76.5 17.2 50.1
C: Optimal non-adaptive − 1.20 15.1 51.6 77.8 17.1 48.8
D: Optimal adaptive − 1.20 12.0 51.0 77.5 14.5 47.7
5 A: ρ-family, equal groups 1.22 1.20 24.0 53.4 73.2 24.1 50.2
B: ρ-family, opt. 1st group 1.20 1.20 14.2 54.2 74.1 16.6 48.3
C: Optimal non-adaptive − 1.20 12.5 49.4 76.1 15.0 46.8
D: Optimal adaptive − 1.20 9.6 48.6 75.0 12.9 45.5
6 A: ρ-family, equal groups 1.28 1.20 20.0 52.3 72.2 20.3 48.3
B: ρ-family, opt. 1st group 1.26 1.20 13.3 52.8 72.7 16.1 47.2
C: Optimal non-adaptive − 1.20 11.0 48.2 74.5 13.9 45.5
D: Optimal adaptive − 1.20 9.6 46.8 73.1 12.6 44.2
average ASN within 3.2% of nf of the average ASN for any adaptive design meeting the same
conditions on Type I error and power.
Proponents of adaptive tests may turn this comment around and point out the opportunity
to define adaptive designs attaining this extra efficiency. We believe it will be quite a challenge
to find simply defined adaptive procedures with such robustly efficient performance! We
have observed the sampling rules of optimal adaptive tests to be qualitatively different from
rules based on conditional power commonly used in adaptive designs (see also Posch et
al. [14, p. 961]). Some constructions of adaptive tests involve the use of non-sufficient statistics,
again distinguishing them from the optimal adaptive designs — see Tsiatis and Mehta[30].
Thus, some quite new types of adaptive procedure will be needed if this challenge is to be met.
We conclude this section by noting that we have made many further computations using
other weighted combinations of ASNs in place of the criterion (1) and in all cases we have
found qualitatively similar results to those reported here.
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4. EXAMPLES
(a) Normal data. In a randomized trial of cholesterol lowering drugs, patients are assigned
to receive a new compound or an active control. The endpoint is the reduction in cholesterol
level from week zero to week six. The parameter of interest θ = µA − µB is the difference in
mean reductions. From historical data, the patient-to-patient standard deviation of cholesterol
reductions is taken to be σ = 60 mg/dl. We test H0: θ = 0 versus H1: θ > 0 with Type I error
rate α = 0.025. We wish to ensure adequate power 1−β = 0.8 at a minimum clinically relevant
effect size of θ = ∆ = 15 mg/dl, but the improvement is expected to be about 60 mg/dl. Hence
L = 4. From (2), a fixed sample plan would require nf = 2σ2(zα + zβ)2/∆2 = 252 subjects
per treatment arm, a total sample size of 504.
Suppose we choose R = 1.2, allowing an increase of 20% in the maximum sample size to 606
subjects, in order to run a group sequential test with K = 3 analyses and the same Type I
and Type II error rates. With three equally sized groups, the target is 101 subjects per group
on each treatment arm and we see from Table IV that the error spending function parameter
is ρ = 1.19 and average ASN over θ = 0, ∆ and 4∆ is 504× 58.5% = 295 subjects. If however
we choose a first group size of 504× 0.176 = 89 and ρ = 0.92, the average ASN is reduced to
504× 53.9% = 272. The optimal non-adaptive and adaptive tests would lead to average ASNs
of 264 and 261, respectively, quite a meager return on the additional complexity of these two
procedures.
It may be helpful to relate this example to the problem described by Shun et al.[3] to which
we referred in Section 1, bearing in mind that the two effect sizes in the current example are
θ = 15 and 60, rather than the previous θ = 5 and 10. The recommendation in [3] was to start
with a small sample size sufficient to detect the higher effect size, θ = 60 in our example, and
then to decide on a second stage sample size having seen this first set of observations. (In view
of the higher ratio between the optimistic effect size of 60 and minimal clinically significant
effect of 15, it may be advisable to take a somewhat higher initial sample size in this case.)
Suppose such a sampling rule and terminal decision rule are defined and these produce a test
with overall Type I error rate 0.025 and power 0.8 under θ = 15, then we have a 2-group
adaptive design in our class D and Figure 1 and Tables II and IV tell us something about its
properties. From Table II, we see the optimal 2-group adaptive design for criterion (1) with
L = 4 has an overall maximum sample size R = 1.26 times the fixed sample size needed to
achieve power 0.8 at θ = 15, i.e., 1.26 × 504 = 635 subjects, and this results in an average
ASN of 504 × 62.4% = 314. The test constructed following Shun et al’s[3] approach can do
no better than this optimal design and so must have an average ASN of at least 314 subjects.
Also from Table II, we see that a 2-group ρ-family test with R = 1.20 and first group size
164 does almost as well, achieving average ASN of 321. It is noteworthy that the additional
analysis in a 3-group, ρ-family test reduces average ASN to 272 giving a significant advantage
over the optimal 2-stage adaptive test.
(b) Survival data. Suppose a one-sided logrank test is to be used to compare the survival
distributions of subjects on treatment and control arms. The parameter of interest is θ = log λ
where λ is the relative risk (hazard ratio), which is assumed to be constant. We wish to test
H0: θ = 0 versus H1: θ > 0 with Type I error rate α = 0.025. We specify power 1 − β = 0.8
at a minimum clinically relevant effect size of λ = 1.4, i.e., at θ = ∆ = 0.336, but the relative
risk is expected to be λ = 2. Hence L = log 2/ log 1.4 ≈ 2. A fixed sample plan requires,
approximately, a combined total of 4(zα+ zβ)2/∆2 = 278 deaths (or more generally “events”)
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to be observed in the two arms — see [31] or [20, p. 79].
Let us choose an inflation factor R = 1.2 and K = 5 analyses. Thus, with equal numbers of
events between successive analyses, we would need a maximum of 334 events and the target
for the study design would be 67 new events at each analysis. From Table III, we see the error
spending function parameter is ρ = 1.22 and this leads to an average, over the cases θ = 0,
∆ and 2∆, of 152 observed events. In this case, optimizing the number of events at the first
analysis has a negligible effect and there is very little difference between the optimal class A
and class B tests. The optimal non-adaptive and adaptive tests offer small improvements with
average numbers of events equal to 148 and 145, respectively but once again it appears that
the savings are hardly worthwhile to justify the complexity of the class C or D procedures.
5. DISCUSSION
We have posed the problem of how to choose the effect size θ = ∆ at which to specify the
power of a clinical trial when there is disagreement or uncertainty about the likely treatment
effect. Our conclusion when there is a choice between a minimal clinically significant effect size
and larger effect sizes that investigators hope to see is that the power requirement should be
set at the minimal clinically significant effect. This decision may need to be moderated if the
resulting sample size is prohibitive, bearing in mind that a good sequential design will reduce
the observed sample size if the effect size is much larger than the minimal effect size.
In choosing between the available types of experimental design it is the overall power at
θ = ∆ that matters. Proschan and Hunsberger[10] propose “designed extension” procedures
which start with an initial sample size appropriate to a detecting a higher effect size and
continue with a second stage of sampling if first stage results are not decisive, increasing
power to detect lower effect sizes in the process. However, they recognise the importance of
overall power as they present power calculated at a series of possible effect sizes in their Table
2. Our simple observation is that, since the overall power curve determines the effectiveness
of a procedure in detecting treatment effects of different sizes, one may just as well start by
formulating the requirements of a statistical design in terms of its overall power.
Our findings in Section 3 show that, once the power requirement and the effect sizes under
which low ASNs are most important have been specified, the ρ-family of error spending tests
offers a class of very efficient group sequential designs. If the initial group size is chosen
carefully, designs can be obtained which are close to optimal among all non-adaptive group
sequential tests. Since they are defined as error spending tests, these procedures are equipped
to deal with departures from the planned group sizes, while automatically preserving their
Type I error rate and power; see [20, Chap. 7] for more details. Moreover, if the sample size
needed to provide a given power depends on a nuisance parameter, such as the variance of
normal observations, Mehta and Tsiatis[24] show how the “information monitoring” approach
to implementing error spending tests provides a framework for combining group sequential
testing with sample size re-estimation based on updated estimates of the nuisance parameter.
Adding the element of adaptivity to a group sequential design, so that future group sizes are
chosen in the light of current data, can provide a little extra efficiency, but our numerical results
for optimal adaptive tests show that at best this gain is slight. Moreover, we are not aware
of any simply defined adaptive tests which come close to achieving such efficiency. Indeed,
our studies of some of the specific proposals that have been made (e.g. see [17]) indicate that
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ostensibly reasonable adaptation rules can lead to very poor efficiency compared with well
chosen group sequential designs.
A possible benefit of adaptive designs is their flexibility to adapt to information external
to a trial. For example, news of a competing product’s adverse side-effects could lead to
reassessment of the minimum commercially relevant effect size for a drug currently under
study. The flexibility of these tests can also be used to adapt a trial to a change in treatment
definition (such as a new dosage or selection of one dose from an initial range of doses), or to
the substitution of an alternate endpoint; see, for example, Bauer and Ko¨hne[32], Bauer and
Ro¨hmel[33], Fisher[11] and Lehmacher and Wassmer[34]. In another form of adaptation, Wang
et al.[35] use Cui et al’s[8] method to create a group sequential test which can switch adaptively
between hypothesis tests of superiority and non-inferiority. Although conventional group
sequential tests do not accommodate such unplanned adaptation quite as naturally, Denne[36]
and Mu¨ller and Scha¨fer [37, 38] have shown this can be achieved through consideration of the
conditional Type I error rate at an interim analysis.
It is important to distinguish such adaptation from the notion of “adapting to” an internal
estimate of the effect size θ from data in the current trial. This is exactly the interim data
used in defining the group sequential tests and adaptive tests considered in Section 3 and, by
definition, there is no way this information can be used to improve upon the optimal tests
reported there.
The example of a clinical trial for treatment of Parkinson’s disease described in [38, Sec. 4]
provides an interesting final case for discussion. Response was a score from a patient
questionnaire and there was initial uncertainty about the response variance as well as variation
of opinion on the minimum clinically relevant effect. The authors propose an initial group
sequential design which is modified as new estimates of the response variance are obtained.
We are not so convinced by the proposal in their “third scenario” for design modifications
in the light of interim estimates of the effect size. The sample size adaptations are based on
attaining a specific conditional power if the true effect is equal to the lower limit of a confidence
interval for the effect size. This construction produces yet another rule in our class D — but
we have seen that adding an adaptive element offers little scope for improving efficiency over
that of a well chosen GST and we have warned that some adaptive schemes can be quite
inefficient. More significantly, this adaptation does nothing to resolve the original difference of
opinion concerning the minimum clinically relevant effect: interim estimates provide (rather
noisy) information about the true effect size, not about the range of values to be regarded as
clinically significant.
REFERENCES
1. Senn S Statistical Issues in Drug Development Wiley: Chichester, 1997.
2. Piantadosi S. Clinical Trials: A Methodologic Perspective. Wiley: New York, 1997.
3. Shun Z, Yuan W, Brady WE and Hsu H. Type I error in sample size reestimations based on observed
treatment difference (with commentary). Statistics in Medicine 2001; 20: 497–513. Rejoinder: 519–520.
4. Pocock, S. Clinical Trials: A Practical Approach. Wiley: Chichester, 1997.
5. Food and Drug Administration. E9: Statistical Principles for Clinical Trials. Federal Register 1998; 63(179):
49583–49598, (16 September, 1998).
6. Anderson K and Liu Q. Optimal adaptive vs optimal group sequential design. Conference on Adaptive
Design for Clinical Trials; Philadelphia (March 4–5, 2004).
7. Liu Q and Chi GYH. On sample size and inference for two-stage adaptive designs. Biometrics 2001; 57:
172–177.
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
Prepared using simauth.cls
16 C. JENNISON AND B. W. TURNBULL
8. Cui L, Hung HMJ and Wang, S-J. Modification of sample size in group sequential clinical trials. Biometrics
1999; 55: 853–857.
9. Bauer P. Multistage testing with adaptive designs (with discussion). Biometrie und Informatik in Medizin
und Biologie 1989; 20: 130–148.
10. Proschan MA and Hunsberger SA. Designed extension of studies based on conditional power. Biometrics
1995; 51: 1315–1324.
11. Fisher LD. Self-designing clinical trials. Statistics in Medicine 1998; 17: 1551–1562.
12. Wassmer G. Basic concepts of group sequential and adaptive group sequential test procedures. Statistical
Papers 2000; 41: 253–279.
13. Li G, Shih WJ, Xie T and Lu J. A sample size adjustment procedure for clinical trials based on conditional
power. Biostatistics 2002; 3: 277–287.
14. Posch M, Bauer P and Brannath W. Issues in designing flexible trials. Statistics in Medicine 2003; 22:
953–969.
15. Shen Y and Fisher L. Statistical inference for self-designing designing clinical trials with a one-sided
hypothesis. Biometrics 1999; 55: 190–197.
16. Shih WJ. Sample size re-estimation — journey for a decade. Statistics in Medicine 2001; 20: 515–518.
17. Jennison C and Turnbull BW. Mid-course sample size modification in clinical trials based on the observed
treatment effect. Statistics in Medicine 2003; 22: 971–993.
18. Schmitz N. Optimal Sequentially Planned Decision Procedures. Lecture Notes in Statistics, 79, Springer-
Verlag: New York, 1993.
19. Scha¨fer, H. and Mu¨ller, H-H. Construction of group sequential designs in clinical trials on the basis of
detectable treatment differences. Statistics in Medicine 2004; 23: 1413–1424.
20. Jennison C and Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman
& Hall/CRC: Boca Raton, 2000.
21. Wittes J and Brittain E. The role of internal pilot studies in increasing efficiency of clinical trials. Statistics
in Medicine 1990; 9: 65–72.
22. Gould AL and Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes
with unknown variance. Communications in Statistics (A) – Theory and Methods 1992; 21: 2833-2853.
23. Denne JS and Jennison C. A group sequential t-test with updating of sample size. Biometrika 2000; 87:
125–34.
24. Mehta CR and Tsiatis AA. Flexible sample size considerations using information-based interim monitoring.
Drug Information Journal 2001; 35: 1095–112.
25. Schwartz TA and Denne JS. Common threads between sample size recalculation and group sequential
procedures. Pharmaceutical Statistics 2003; 2: 263–271.
26. Cytel Software Corp. EaSt v.3: Software for the Design, Simulation and Interim Monitoring of Flexible
Clinical Trials. Cambridge, Massachusetts, 2003.
27. Insightful Corp. S+SeqTrial 2.0. Seattle, Washington, 2002.
28. Eales JD and Jennison C. An improved method for deriving optimal one-sided group sequential tests.
Biometrika 1992; 79: 13–24.
29. Barber S and Jennison C. Optimal asymmetric one-sided group sequential tests. Biometrika 2002; 89:
49–60.
30. Tsiatis AA and Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika
2003; 90: 367–378.
31. Schoenfeld DA and Richter JR. Nomograms for calculating the number of patients needed for a clinical
trial with survival as an endpoint. Biometrics 1982; 38: 163–170.
32. Bauer P and Kohne K. Evaluations of experiments with adaptive interim analyses. Biometrics 1994; 50:
1029–1041. Correction; 52: 380.
33. Bauer P and Rohmel J. An adaptive method for establishing a dose-response relationship. Statistics In
Medicine 1995; 14: 1595–1607.
34. Lehmacher W and Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics
1999; 55: 1286–1290.
35. Wang S-J, Hung HMJ, Tsong Y and Cui L. Group sequential test strategies for superiority and non-
inferiority hypotheses in active controlled clinical trials. Statistics in Medicine 2001; 20: 1903–1912.
36. Denne JS. Sample size recalculation using conditional power. Statistics in Medicine 2001; 20: 2645–2660.
37. Mu¨ller H-H and Scha¨fer H. Adaptive group sequential designs for clinical trials: Combining the advantages
of adaptive and of classical group sequential procedures. Biometrics 2001; 57: 886–891.
38. Mu¨ller, H-H. and Scha¨fer, H. A general principle for changing a design any time during the course of a
clinical trial. Statistics in Medicine 2004; 23: 2497–2508.
Copyright c© 2000 John Wiley & Sons, Ltd. Statist. Med. 2000; 00:1–6
Prepared using simauth.cls
